Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
ACE-031 (ramatercept) is a soluble fusion protein of the activin receptor IIB (ActRIIB) extracellular domain and human IgG1 Fc, developed by Acceleron Pharma as a myostatin/activin ligand trap for muscle-wasting disorders. Clinical development was HALTED in 2011 after unexpected vascular adverse events (epistaxis, telangiectasia) attributed to off-target BMP-9/10 inhibition. NOT FDA-approved; all further development was terminated. Now sold only as a grey-market research chemical. WADA-prohibited (myostatin inhibitor).
Lowest Price
$99.99
Highest Price
$173.00
Average Price
$144.66
Potential Savings
42%
across 3 options
0 of 3 vendors are lab-verified for ACE-031
We cross-check each vendor's Certificate of Analysis against the issuing lab's own verification portal — so “cheapest” isn't the only signal.
Best price trend
Lowest $/mg for ACE-031 · last 45 days
$3.20/mg
▼ 97% vs 45d ago
Trust grade first, cheapest within grade
vial · 10mgzztai-tech.com· price updated today
$3.20/mg
vial · 1mgpeptidetech.co· price updated 2d ago
$99.99/mg
97% more per mg
vial · 1mgbiotechpeptides.com· price updated today
$161.00/mg
98% more per mg
vial · 1mgcorepeptides.com· price updated today
$173.00/mg
98% more per mg
Prices are estimates and may vary. For research use only. We may earn a commission on purchases through affiliate links. Not medical advice.
Check formulation: Lyophilized powder requires reconstitution before use. Pre-mixed solutions are more convenient but may have a shorter shelf life and higher prices.
Compare per-mg cost: Different strengths and quantities make direct price comparison difficult. Calculate the per-milligram cost to find the true best value.
Verify COAs: Look for vendors that publish per-batch Certificates of Analysis from named, accredited labs. Every vendor on this page is verified for endotoxin testing — not just HPLC purity.
Phase 2 in ambulatory boys with Duchenne muscular dystrophy was terminated early in 2011 after unexpected nose-bleeds and telangiectasia were observed (attributed to off-target BMP-9/10 neutralization); published results later showed no significant 6MWT benefit vs. placebo in the truncated trial (Campbell et al., Muscle & Nerve, 2017; PMID 27462804). A single-ascending-dose Phase 1 study in healthy postmenopausal women (Attie et al., Muscle & Nerve, 2013; PMID 23169607) showed dose-dependent modest lean-mass increase but also the same vascular signal. Acceleron formally discontinued ACE-031 in 2013 and pivoted to other ActRII programs. No FDA approval; development TERMINATED for vascular safety. WADA-prohibited.
This platform provides informational tools only, not medical advice.
Prices verified as of June 2026. Actual prices may vary. For research use only.
Disclosed Labs